Lung cancer vaccines and gene therapy

Lung Cancer

Volumn 41, Issue SUPPL. 1, 2003, Pages 103-113

  Hege, Kristen M ^a   Carbone, David P ^b  

^a CELL GENESYS INC   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

BEC2; Gene therapy; GVAX ; HSV tk; Lung cancer; Mage 3; MUC1; ONYX 015; p53; Tumor vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; MELANOMA ANTIGEN 3; MUCIN 1; PROTEIN BEC2; PROTEIN P53; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER GENETICS; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; GENE THERAPY; HUMAN; IMMUNOGENETICS; LUNG CARCINOMA; PRIORITY JOURNAL; SUICIDE GENE; VACCINATION;

EID: 0038350394     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00153-3     Document Type: Conference Paper

References (62)

1. Kolb H., Schattenberg A., Goldman J., et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 86:1995;4011-4013.
2. Albelda S., Wiewrodt R., Sterman D. Gene therapy for lung neoplasms. Lung Cancer. 23:2002;265-277.
3. Dranoff G., Jaffee E., Lazenby A., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA. 90:1993;3539-3543.
4. Machiels J., Reilly R., Emens L., et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 61:2001;3689-3697.
5. Soiffer R., Lynch T., Mihm M., et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA. 95:1998;13141-13146.
6. Simons J., Jaffee E., Weber C., et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 57:1997;1537-1546.
7. Jaffee E., Hruban R., Laheru D., et al. Novel allogeneic GM-CSF-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J. Clin. Oncol. 19:2001;145-156.
8. Salgia R., Lynch T., Skarin A., et al. Vaccination with irradiated autologous tumor cells engineered to secrete Granulocyte-Macrophage Colony Stimulating Factor augments anti-tumor immunity in patients with metastatic non-small cell lung carcinoma. J. Clin. Oncol. 21:2003;624-630.
9. Simons J., Bahar M., Chang J., et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59:1999;5160-5168.
10. Borrello I., Sotomayor E., Cooke S., et al. A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum. Gene Ther. 10:1999;1983-1991.
11. Nemunaitis J., Sterman D., Jablons D., et al. A phase I/II study of autologous GM-CSF gene-modified cancer vaccines in subjects with non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20:2001;255a.
12. Nobel T.A., Perk K. Bronchioloalveolar cell carcinoma. Animal model: pulmonary adenomatosis of sheep, pulmonary carcinoma of sheep (jaagsiekte). Am. J. Pathol. 90:1978;783-786.
13. Stinson J., Leibovitz A., Brindley G., et al. Filamentous particles in human alveolar cell carcinomas: electron microscopy studies of six cases (preliminary report). J. Natl. Cancer Inst. 49:1972;1483-1493.
14. Jaffee E., Thomas M., Huang A., et al. Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J. Immunother. Emphasis Tumor Immunol. 19:1996;176-183.
15. Ding L., Lalani E.N., Reddish M., et al. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol. Immunother. 36:1993;9-17.
16. Palmer M., Parker J., Modi S., et al. Phase I study of the BLP25 (MUC1 Peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin. Lung Cancer. 3:2001;49-57.
17. Krug L.M., Grant S.C., Miller V.A., et al. Strategies to eradicate minimal residual disease in small cell lung cancer: high-dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors, and BEC2 plus BCG vaccination. Semin. Oncol. 26:1999;55-61.
18. Gaugler B., Van den Eynde B., Van der Bruggen P., et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179:1994;921-930.
19. Gotoh K., Yatabe Y., Sugiura T., et al. Frequency of MAGE-3 gene expression in HLA-A2 positive patients with non-small cell lung cancer. Lung Cancer. 20:1998;117-125.
20. Yoshimatsu T., Yoshino I., Ohgami A., et al. Expression of the melanoma antigen-encoding gene in human lung cancer. J. Surg. Oncol. 67:1998;126-129.
21. Marchand M., Van Baren N., Weynants P., et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer. 80:1999;219-230.
22. O'Brien M.E., Saini A., Smith I.E., et al. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br. J. Cancer. 83:2000;853-857.
23. Watson S., Michaeli D., Grimes S., et al. Gastrimmune raises antibodies that neutralise amidated and glycine-extended gastrin-17 and inhibit the growth of colon cancer. Cancer Res. 56:1996;880-885.
24. Smith A., Justin T., Michaeli D., et al. Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer. Clin. Cancer Res. 6:2000;4719-4724.
25. Ishida T., Chada S., Stipanov M., et al. Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses. Clin. Exp. Immunol. 117:1999;244-251.
26. Nikitina E., Clark J., Van Beynen J., et al. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin. Cancer Res. 1:2001;2-4.
27. Dickler M., Ragupathi G., Liu N., et al. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin. Cancer Res. 5:1999;2773-2779.
28. Tan Y., Xu M., Wang W., et al. IL-2 gene therapy of advanced lung cancer patients. Anticancer Res. 16:1996;1993-1998.
29. Miller P.W., Sharma S., Stolina M., et al. Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum. Gene Ther. 11:2000;53-65.
30. Marshall J.L., Arlen P.M., Rizvi N., et al. A phase I study of sequential vaccinations with fowlpox-CEA (6D)-Tricom (B7/ICAM/LFA3) alone, and in combination with vaccinia-CEA (6D)-Tricom and GM-CSF in patients with CEA expressing carcinomas. Proc. Am. Soc. Clin. Oncol. 21:2002;7a.
31. Robinson B., Mukherjee S., Davidson A., et al. Cytokine gene therapy or infusion as treatment for solid human cancer. J. Immunother. 21:1998;211-217.
32. Swisher S., Roth J. Clinical update of Ad-p53 gene therapy for lung cancer. Surg. Oncol. Clin. North Am. 11:2002;521-535.
33. Fujiwara T., Cai D., Georges R., et al. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J. Natl. Cancer Inst. 86:1994;1458-1462.
34. Zhang W., Fang X., Mazur W., et al. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther. 1:1994;5-13.
35. Roth J., Nguyen D., Lawrence D., et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med. 2:1996;985-991.
36. Schuler M., Rochlitz C., Horowitz J., et al. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum. Gene Ther. 9:1998;2075-2082.
37. Swisher S., Roth J., Nemunaitis J., et al. Adenovirus-mediated p53 gene transfer in advanced non-small cell lung cancer. J. Natl. Cancer Inst. 91:1999;763-771.
38. Gahery-Segard H., Molinier-Frenkel V., Le Bourlaire C., et al. Phase 1 trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J. Clin. Invest. 100:1997;2218-2226.
39. Tursz T., Le Cesne A., Baldeyrou P., et al. Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. J. Natl. Cancer Inst. 88:1996;1857-1863.
40. Kubba S., Adak S., Schiller J. Phase I trial of adenovirus p53 in bronchioloalveolar cell lung carcinoma (BAC) administered by bronchoalveolar lavage. Proc. Am. Soc. Clin. Oncol. 19:2000;487a.
41. Lee H., Suh Y., Ji L., et al. Inhibition of oncogenic K-ras signaling by aerosolized gene delivery in a mouse model of human lung cancer. Clin. Cancer Res. 8:2002;2907-2975.
42. Gautam A., Densmore C., Melton S., et al. Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis. Cancer Gene Ther. 9:2002;28-36.
43. Nemunaitis J., Swisher S., Timmons T., et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J. Clin. Oncol. 18:2000;609-622.
44. Schuler M., Herrmann R., DeGreve J., et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small cell lung cancer; results of a multicenter phase II study. J. Clin. Oncol. 19:2001;1750-1758.
45. Swisher S., Roth J., Komaki R. A phase II trial of adenoviral mediated p53 gene transfer (RPR/INGN 201) in conjunction with radiation therapy in patients with localized non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 19:2000;461a.
46. Swisher S., Roth J., Komaki R. Induction of pro-apoptotic mediators and tumor regression following intratumoral delivery of adenoviral p53 (RPR/INGN 201) and radiation therapy in patients with non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20:2000;257a.
47. Ramesh F., Saeki T., Templeton N. Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppression genes using an improved liposome vector. Mol. Ther. 3:2001;337-350.
48. Nemunaitis J., Cunningham C., Buchanan A., et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther. 8:2001;746-759.
49. Hwang H., Smythe W., Elshami A., et al. Gene therapy using adenovirus carrying the herpes simplex thymidine kinase gene to treat in vitro models of human malignant mesothelioma and lung cancer. Am. J. Respir. Cell. Mol. Biol. 13:1995;7-16.
50. Pope I., Poston G., Kinsella A. The role of the bystander effect in suicide gene therapy. Eur. J. Cancer. 33:1997;1005-1016.
51. Fukunaga M., Takamori S., Hayashi A., et al. Adenoviral herpes simplex virus thymidine kinase gene therapy in an orthotopic lung cancer model. Ann. Thorac. Surg. 73:2002;1740-1746.
52. Sterman D., Treat J., Litzky L., et al. Adenovirus-mediated herpes simplex virus thymidine kinase gene delivery in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum. Gene Ther. 9:1998;1083-1092.
53. Sterman D., Molnar-Kimber K., Iyengar T., et al. A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma. Cancer Gene Ther. 7:2000;1511-1518.
54. Rosenberg S., Lotze M., Muul L., et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New Engl. J. Med. 316:1987;889-897.
55. Escudier B., Le Chavalier T., Angevin F. Lung Cancer. 29:(Supp 1):2000;184. abstract 622.
56. O'Reilly M., Holmgren L., Chen C., et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature. Med. 2:1996;689-692.
57. O'Reilly M. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:1997;277-285.
58. Folkman J. Antiangiogenic gene therapy. Proc. Natl. Acad. Sci. USA. 95:1998;9064-9066.
59. Hood J.D., Bednarski M., Frausto R., et al. Tumor regression by targeted gene delivery to the neovasculature. Science. 296:2002;2404-2407.
60. Brooks P., Montgomery A., Rosenfeld M., et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 79:1994;1157-1164.
61. Huser M., Luckett J., Chiloeches A., et al. MEK kinase activity is not necessary for Raf-1 function. EMBO J. 20:2001;1940-1951.
62. Niethammer A.G., Xiang R., Becker J.C., et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat. Med. 8:2002;1369-1375.